^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    M6123

    i
    Other names: M6123, M 6123, M-6123
    Company:
    EMD Serono, Ligand
    Drug class:
    FGFR1 antagonist
    3years
    FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. (PubMed, Eur J Cancer)
    Finally, NSCLC PDX models demonstrating FGFR1 amplification and FGFR1 protein overexpression were sensitive to M6123. The unique molecular and immune features of tumours with high FGFR1 expression provide a rationale to stratify patients in future clinical trials of FGFR1 pathway-targeting agents.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • FGFR1 amplification • FGFR1 overexpression • FGFR1 expression
    |
    M6123
    4years
    [VIRTUAL] M6123, a selective FGFR1 antagonist, demonstrates anti-tumor activity as monotherapy and in combination with chemotherapy in mesothelioma models (AACR-II 2020)
    Despite the poor prognosis and increasing incidence of this disease, the combination of pemetrexed with cisplatin currently remains the only available treatment option to patients. In summary, M6123 showed favorable anti-tumor activity in preclinical models of mesothelioma, in particular in combination with standard of care chemotherapy. Further preclinical testing is warranted to confirm a predictive biomarker signature for selection of mesothelioma patients that may benefit from addition of M6123.
    Combination therapy
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    cisplatin • pemetrexed • M6123